新型脑保护剂依达拉奉治疗放射性脑病的临床研究

Treatment of radiation encephalopathy with edaravone as a new brain protective agent

目的探讨新型脑保护剂依达拉奉治疗放射性脑病的疗效。方法将42例鼻咽癌放疗后放射性脑病患者随机分为试验组(传统常规治疗方法合用依达拉奉)和对照组(传统常规治疗方法)。观察两组治疗前后的临床评分、凝血功能指标、头颅磁共振以及世界卫生组织生存质量测定量表简表(WHOQOL-BREF)评分的变化。结果试验组临床治疗的显效率(50．0%)和总有效率(88．9%)明显高于对照组(14．3%和42．9%)；头颅MRI显示治疗后实验组病灶体积较对照组明显缩小；WHOQOL-BREF评分显示在生理、心理、社会环境、总的生活评分方面试验组均较对照组有明显的改善：且两组在凝血功能方面无明显差异。结论依达拉奉对放射性脑病的治疗具有明显的效果。

Objective To study the therapeutic effect ofedaravone, a new kind of brain protective agent, on radiation encephalopathy （REP）. Methods Forty-two patients with REP after radiotherapy for nasopharyngeal carcinoma were divided into experimental （conventional therapy combined with edaravone） and control （conventional therapy only） groups randomly. Then clinical scores, coagulation functional parameters, lesion volume in cranial MRI and WHOQOL-BREF scores were compared before and aiter treatment in the 2 groups. Results The experimental group got a higher excellence （50.0%） and total effective rate （88.9%） than control group （14.3% and 42.9%）. The lesion volume in MRI decreased and the physiological, psychological, social environmental and general living scores increased more in experimental group than those in control group. Furthermore, there was no significant difference in coagulation functional parameters between the 2 groups. Conclusion Edaravone has an obvious therapeutic effect on REP.